|
|
Post by imz72 on Apr 27, 2017 3:26:23 GMT
FlitWays Appoints New Executives: CTO, CFO, & Growth Strategist Officer
CULVER CITY, CA--(Marketwired - Apr 26, 2017) - FlitWays ( OTC PINK : FTWS ), a Los Angeles-based ground travel technology company, today has named Peter Sjolin to a newly created role of chief technology officer (CTO) for the company, Dean Skupen to the newly created role of chief financial officer (CFO), and Gary Rabin as the Growth Strategist. Peter, Dean, and Gary join FlitWays's Senior Leadership Team, reporting directly to FlitWays Chief Executive Officer Tobi Mac. Peter has 22 years of technological experience, including working for major brands like Disney. Dean has 28 years of experience in finance. He was also previously CFO of FlexStylist and Managing Director of Proactive Professional Solutions. Gary has 30 years of experience in growing businesses. He was previously Chairman & CEO of Advanced Cell Technology."We are thrilled that Peter, Dean, and Gary are coming onboard to help lead FlitWays. They each bring to FlitWays their unique expertise that empower organizations, and help us in our next phase of growth. FlitWays aims to be the leader in enterprise ground transportation solutions for businesses and corporations. With their combined experience, we are excited to have them as part of the FlitWays team moving forward," Tobi Mac said. Peter Sjolin will lead the company's global technological initiatives, to continue optimizing the platform. Dean Skupen will take charge of FlitWays financial projects and requirements. Gary Rabin will take lead of FlitWays global growth initiatives and work with the FlitWays team to become the preeminent global ground transportation solution provider for businesses and corporations.About FlitWays:
FlitWays Technology Inc. provides both corporate enterprises and their employees and global travel resellers and their customers with a complete offering of fully integrated ground transportation solutions for any budget or need. FlitWays built a sophisticated software platform to give customers enterprise suite and app-based booking, billing, expense management and real-time monitoring for a simple to use ground transportation offering. FlitWays combined that with its proprietary global network of private car, limousine, taxi and ride sharing service providers. This allows FlitWays clients to have a solution that mimics the simplicity of workflow for airline and hotel travel, removing the manual, complex and time consuming nature of traditional ground transportation. FlitWays offering not only helps its customers, but provides car service owners and drivers better utilization of their equity. FlitWays give travelers an array of classes of cars, pick-up options and payment options, all fully integrated to corporate expense and travel management systems. FlitWays' objective is to take an antiquated market and bring it into line with the advanced and seamless methodology of the other key components of the travel experience. For additional information regarding FlitWays, visit www.FlitWays.com. finance.yahoo.com/news/flitways-appoints-executives-cto-cfo-120000340.html
|
|
|
|
Post by imz72 on Apr 27, 2017 3:37:15 GMT
A Blast from the Past:
|
|
|
|
Post by JHam on Apr 27, 2017 3:44:56 GMT
FlitWays Appoints New Executives: CTO, CFO, & Growth Strategist Officer
CULVER CITY, CA--(Marketwired - Apr 26, 2017) - FlitWays ( OTC PINK : FTWS ), a Los Angeles-based ground travel technology company, today has named Peter Sjolin to a newly created role of chief technology officer (CTO) for the company, Dean Skupen to the newly created role of chief financial officer (CFO), and Gary Rabin as the Growth Strategist. Peter, Dean, and Gary join FlitWays's Senior Leadership Team, reporting directly to FlitWays Chief Executive Officer Tobi Mac. Peter has 22 years of technological experience, including working for major brands like Disney. Dean has 28 years of experience in finance. He was also previously CFO of FlexStylist and Managing Director of Proactive Professional Solutions. Gary has 30 years of experience in growing businesses. He was previously Chairman & CEO of Advanced Cell Technology."We are thrilled that Peter, Dean, and Gary are coming onboard to help lead FlitWays. They each bring to FlitWays their unique expertise that empower organizations, and help us in our next phase of growth. FlitWays aims to be the leader in enterprise ground transportation solutions for businesses and corporations. With their combined experience, we are excited to have them as part of the FlitWays team moving forward," Tobi Mac said. Peter Sjolin will lead the company's global technological initiatives, to continue optimizing the platform. Dean Skupen will take charge of FlitWays financial projects and requirements. Gary Rabin will take lead of FlitWays global growth initiatives and work with the FlitWays team to become the preeminent global ground transportation solution provider for businesses and corporations.About FlitWays:
FlitWays Technology Inc. provides both corporate enterprises and their employees and global travel resellers and their customers with a complete offering of fully integrated ground transportation solutions for any budget or need. FlitWays built a sophisticated software platform to give customers enterprise suite and app-based booking, billing, expense management and real-time monitoring for a simple to use ground transportation offering. FlitWays combined that with its proprietary global network of private car, limousine, taxi and ride sharing service providers. This allows FlitWays clients to have a solution that mimics the simplicity of workflow for airline and hotel travel, removing the manual, complex and time consuming nature of traditional ground transportation. FlitWays offering not only helps its customers, but provides car service owners and drivers better utilization of their equity. FlitWays give travelers an array of classes of cars, pick-up options and payment options, all fully integrated to corporate expense and travel management systems. FlitWays' objective is to take an antiquated market and bring it into line with the advanced and seamless methodology of the other key components of the travel experience. For additional information regarding FlitWays, visit www.FlitWays.com. finance.yahoo.com/news/flitways-appoints-executives-cto-cfo-120000340.html Wow. Surprised they didn't write; Gary was fined by the SEC for stealing from investors... |
|
|
|
Post by hansgruber on May 3, 2017 13:34:50 GMT
SO GB is now working for a glorified uber? interesting. I looked up this company. $4 million market cap. On the pink sheets. Seems like a possible scam where gullible investors can be fleeced out of their money and insiders can get away with selling stock without reporting sales. Seems like the perfect gig for GB. I guess his restaurant went to crap?
|
|
|
|
Post by hansgruber on May 3, 2017 13:37:49 GMT
Yep. According to yelp his restaurant close a few years ago. On to the next scam. I guess professional poker didn't work out either. This guy is a clown of epic proportions.
|
|
dave
Junior Member
Posts: 87 
|
Post by dave on May 7, 2017 15:36:40 GMT
a very wealthy clown
|
|
|
|
Post by CM kipper007 on May 11, 2017 17:59:43 GMT
He might be a clown, but as careers go, he is more successful than me.
|
|
|
|
Post by JHam on May 11, 2017 22:12:26 GMT
He might be a clown, but as careers go, he is more successful than me. I'd rather be not successful than a "successful" lying scam artist. |
|
|
|
Post by RLC on May 11, 2017 22:19:16 GMT
He might be a clown, but as careers go, he is more successful than me. I'd rather be not successful than a "successful" lying scam artist. Couldn't agree more! |
|
|
|
Post by imz72 on Apr 17, 2019 1:59:36 GMT
Just stumbled upon Gary's name again... ____________________________________________ Immune Pharmaceuticals Announces Leadership Transition
FORT LEE, NJ (March 7, 2019) - Immune Pharmaceuticals, Inc. (OTC PINK: IMNPQ) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that Gary Rabin has been appointed as President and interim Chief Executive Officer (CEO) and a member of the Board of Directors. He succeeds Tony Fiorino, MD, PhD, Immune’s former President and interim CEO, who has resigned as an officer of the Company but will remain a Director. On February 17, 2019, the Company filed a filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of New Jersey (Case No. 19-13273). Dr. Fiorino noted “At this point in time, Immune needs executive leadership well-versed in corporate restructuring, asset sales and the bankruptcy process. The Company is fortunate to have found Gary Rabin, who brings a wealth of relevant experience to the table. Gary has previously served as a consultant to the Company and has a deep understanding of the Company’s programs, capital structure, restructuring efforts to date, and the chapter 11 process. In my ongoing role as a Director, I intend to focus on the Company’s efforts to sell or partner the Company’s clinical assets.” Gary H. Rabin, 53, has a 32-year career in finance, investing, biotechnology management, and financial restructuring. He has been the Managing Member of Vine Holdings Group since 2015. Previously he was the Chairman and CEO of Advanced Cell Technology, Inc., a biotechnology company in the cell therapy industry, where he led a successful financial turnaround. He has also been the portfolio manager of three hedge funds in the tech/media/telecom sector. From 1987 until 2002, he was a media and telecom investment banker for some of the world’s largest investment banking firms including CIBC, ING Barings, UBS and First Boston. About Immune Pharmaceuticals, Inc.
Immune Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that targets eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By blocking eotaxin-1, bertilimumab may prevent the migration and activation of eosinophils and other cells, thus blocking an important inflammatory pathway active in a variety of allergic and immune diseases. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. For more information, please visit www.immunepharma.com and connect with the Company on Twitter, LinkedIn, and Facebook. www.immunepharma.com/news-events/press-releases/detail/180/immune-pharmaceuticals-announces-leadership-transitionImmune Pharmaceuticals, Inc. (IMNPQ) on Yahoo Finance: finance.yahoo.com/quote/IMNPQ?p=IMNPQ&.tsrc=fin-srch |
|
|
|
Post by JHam on Apr 17, 2019 5:41:12 GMT
Just stumbled upon Gary's name again... ____________________________________________ Immune Pharmaceuticals Announces Leadership Transition
FORT LEE, NJ (March 7, 2019) - Immune Pharmaceuticals, Inc. (OTC PINK: IMNPQ) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that Gary Rabin has been appointed as President and interim Chief Executive Officer (CEO) and a member of the Board of Directors. He succeeds Tony Fiorino, MD, PhD, Immune’s former President and interim CEO, who has resigned as an officer of the Company but will remain a Director. On February 17, 2019, the Company filed a filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of New Jersey (Case No. 19-13273). Dr. Fiorino noted “At this point in time, Immune needs executive leadership well-versed in corporate restructuring, asset sales and the bankruptcy process. The Company is fortunate to have found Gary Rabin, who brings a wealth of relevant experience to the table. Gary has previously served as a consultant to the Company and has a deep understanding of the Company’s programs, capital structure, restructuring efforts to date, and the chapter 11 process. In my ongoing role as a Director, I intend to focus on the Company’s efforts to sell or partner the Company’s clinical assets.” Gary H. Rabin, 53, has a 32-year career in finance, investing, biotechnology management, and financial restructuring. He has been the Managing Member of Vine Holdings Group since 2015. Previously he was the Chairman and CEO of Advanced Cell Technology, Inc., a biotechnology company in the cell therapy industry, where he led a successful financial turnaround. He has also been the portfolio manager of three hedge funds in the tech/media/telecom sector. From 1987 until 2002, he was a media and telecom investment banker for some of the world’s largest investment banking firms including CIBC, ING Barings, UBS and First Boston. About Immune Pharmaceuticals, Inc.
Immune Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that targets eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By blocking eotaxin-1, bertilimumab may prevent the migration and activation of eosinophils and other cells, thus blocking an important inflammatory pathway active in a variety of allergic and immune diseases. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. For more information, please visit www.immunepharma.com and connect with the Company on Twitter, LinkedIn, and Facebook. www.immunepharma.com/news-events/press-releases/detail/180/immune-pharmaceuticals-announces-leadership-transitionImmune Pharmaceuticals, Inc. (IMNPQ) on Yahoo Finance: finance.yahoo.com/quote/IMNPQ?p=IMNPQ&.tsrc=fin-srchLooks like Gary found another pink sheet stock he can get rich off of... |
|
|
|
Post by nateb on Apr 27, 2019 17:13:46 GMT
Just stumbled upon Gary's name again... ____________________________________________ Immune Pharmaceuticals Announces Leadership Transition
FORT LEE, NJ (March 7, 2019) - Immune Pharmaceuticals, Inc. (OTC PINK: IMNPQ) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that Gary Rabin has been appointed as President and interim Chief Executive Officer (CEO) and a member of the Board of Directors. He succeeds Tony Fiorino, MD, PhD, Immune’s former President and interim CEO, who has resigned as an officer of the Company but will remain a Director. On February 17, 2019, the Company filed a filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of New Jersey (Case No. 19-13273). Dr. Fiorino noted “At this point in time, Immune needs executive leadership well-versed in corporate restructuring, asset sales and the bankruptcy process. The Company is fortunate to have found Gary Rabin, who brings a wealth of relevant experience to the table. Gary has previously served as a consultant to the Company and has a deep understanding of the Company’s programs, capital structure, restructuring efforts to date, and the chapter 11 process. In my ongoing role as a Director, I intend to focus on the Company’s efforts to sell or partner the Company’s clinical assets.” Gary H. Rabin, 53, has a 32-year career in finance, investing, biotechnology management, and financial restructuring. He has been the Managing Member of Vine Holdings Group since 2015. Previously he was the Chairman and CEO of Advanced Cell Technology, Inc., a biotechnology company in the cell therapy industry, where he led a successful financial turnaround. He has also been the portfolio manager of three hedge funds in the tech/media/telecom sector. From 1987 until 2002, he was a media and telecom investment banker for some of the world’s largest investment banking firms including CIBC, ING Barings, UBS and First Boston. About Immune Pharmaceuticals, Inc.
Immune Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that targets eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By blocking eotaxin-1, bertilimumab may prevent the migration and activation of eosinophils and other cells, thus blocking an important inflammatory pathway active in a variety of allergic and immune diseases. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. For more information, please visit www.immunepharma.com and connect with the Company on Twitter, LinkedIn, and Facebook. www.immunepharma.com/news-events/press-releases/detail/180/immune-pharmaceuticals-announces-leadership-transitionImmune Pharmaceuticals, Inc. (IMNPQ) on Yahoo Finance: finance.yahoo.com/quote/IMNPQ?p=IMNPQ&.tsrc=fin-srchJeeze, with his sordid past.. how is this guy still employable? I guess there's hope for even the worst of us with a good dose of revisionist history. |
|
